These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 16799778)

  • 1. Anti-tumour necrosis factor-alpha therapy over conventional therapy improves endothelial function in adults with rheumatoid arthritis.
    Bilsborough W; Keen H; Taylor A; O'Driscoll GJ; Arnolda L; Green DJ
    Rheumatol Int; 2006 Oct; 26(12):1125-31. PubMed ID: 16799778
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-tumor necrosis factor-α therapy and changes of flow-mediated vasodilatation in psoriatic and rheumatoid arthritis patients.
    Mazzoccoli G; Notarsanto I; de Pinto GD; Dagostino MP; De Cata A; D'Alessandro G; Tarquini R; Vendemiale G
    Intern Emerg Med; 2010 Dec; 5(6):495-500. PubMed ID: 20845087
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of anti-tumor necrosis factor (TNF)-alpha therapy with etanercept on endothelial functions in patients with rheumatoid arthritis.
    Tikiz H; Arslan O; Pirildar T; Tikiz C; Bayindir P
    Anadolu Kardiyol Derg; 2010 Apr; 10(2):98-103. PubMed ID: 20382605
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sustained improvement of vascular endothelial function during anti-TNFalpha treatment in rheumatoid arthritis patients.
    Sidiropoulos PI; Siakka P; Pagonidis K; Raptopoulou A; Kritikos H; Tsetis D; Boumpas DT
    Scand J Rheumatol; 2009; 38(1):6-10. PubMed ID: 18991190
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial.
    Smolen JS; Kay J; Doyle MK; Landewé R; Matteson EL; Wollenhaupt J; Gaylis N; Murphy FT; Neal JS; Zhou Y; Visvanathan S; Hsia EC; Rahman MU;
    Lancet; 2009 Jul; 374(9685):210-21. PubMed ID: 19560810
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Effect of Treatments for Rheumatoid Arthritis on Endothelial Dysfunction Evaluated by Flow-Mediated Vasodilation in Patients with Rheumatoid Arthritis.
    Kotani K; Miyamoto M; Ando H
    Curr Vasc Pharmacol; 2017; 15(1):10-18. PubMed ID: 27739363
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-TNFalpha therapy in rheumatoid arthritis and autoimmunity.
    Caramaschi P; Biasi D; Colombatti M; Pieropan S; Martinelli N; Carletto A; Volpe A; Pacor LM; Bambara LM
    Rheumatol Int; 2006 Jan; 26(3):209-14. PubMed ID: 15627197
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-tumor necrosis factor-alpha treatment improves endothelial function in patients with rheumatoid arthritis.
    Hürlimann D; Forster A; Noll G; Enseleit F; Chenevard R; Distler O; Béchir M; Spieker LE; Neidhart M; Michel BA; Gay RE; Lüscher TF; Gay S; Ruschitzka F
    Circulation; 2002 Oct; 106(17):2184-7. PubMed ID: 12390945
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High IgA rheumatoid factor levels are associated with poor clinical response to tumour necrosis factor alpha inhibitors in rheumatoid arthritis.
    Bobbio-Pallavicini F; Caporali R; Alpini C; Avalle S; Epis OM; Klersy C; Montecucco C
    Ann Rheum Dis; 2007 Mar; 66(3):302-7. PubMed ID: 17079248
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Copernican revolution in the therapy of rheumatoid arthritis: the contribution of anti-TNFalpha drugs].
    Bombardieri S; Ferraccioli G; Ferri C; Galeazzi M; Lapadula G; Cerinic MM; Montecucco C; Triolo G; Trotta F; Valentini G
    Reumatismo; 2009; 61 Suppl 1():1-23. PubMed ID: 19999184
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of inflammation and cardiovascular disease risk on microvascular and macrovascular endothelial function in patients with rheumatoid arthritis: a cross-sectional and longitudinal study.
    Sandoo A; Kitas GD; Carroll D; Veldhuijzen van Zanten JJ
    Arthritis Res Ther; 2012 May; 14(3):R117. PubMed ID: 22594788
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Anti-TNF alpha agents in patients with rheumatoid arthritis refractory to conventional therapies].
    González-Gay MA; Agudo M
    Med Clin (Barc); 2010 May; 134(15):684-5. PubMed ID: 20176386
    [No Abstract]   [Full Text] [Related]  

  • 13. TNF-alpha blockade induces a reversible but transient effect on endothelial dysfunction in patients with long-standing severe rheumatoid arthritis.
    Bosello S; Santoliquido A; Zoli A; Di Campli C; Flore R; Tondi P; Ferraccioli G
    Clin Rheumatol; 2008 Jul; 27(7):833-9. PubMed ID: 18075712
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical improvement in rheumatoid arthritis is associated with healthier microvascular function in patients who respond to antirheumatic therapy.
    Galarraga B; Belch JJ; Pullar T; Ogston S; Khan F
    J Rheumatol; 2010 Mar; 37(3):521-8. PubMed ID: 20080919
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modern treatment strategies in rheumatoid arthritis.
    Hetland ML
    Dan Med Bull; 2011 Nov; 58(11):B4320. PubMed ID: 22047935
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents.
    Strangfeld A; Listing J; Herzer P; Liebhaber A; Rockwitz K; Richter C; Zink A
    JAMA; 2009 Feb; 301(7):737-44. PubMed ID: 19224750
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Etanercept maintains the clinical benefit achieved by infliximab in patients with rheumatoid arthritis who discontinued infliximab because of side effects.
    Iannone F; Trotta F; Montecucco C; Giacomelli R; Galeazzi M; Matucci-Cerinic M; Ferri C; Cutolo M; Maria Bambara L; Triolo G; Ferraccioli G; Valentini G; Lapadula G;
    Ann Rheum Dis; 2007 Feb; 66(2):249-52. PubMed ID: 16837489
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-nuclear antibodies, anti-DNA and C4 complement evolution in rheumatoid arthritis and ankylosing spondylitis treated with TNF-alpha blockers.
    Gonnet-Gracia C; Barnetche T; Richez C; Blanco P; Dehais J; Schaeverbeke T
    Clin Exp Rheumatol; 2008; 26(3):401-7. PubMed ID: 18578960
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lack of adverse effect of anti-tumor necrosis factor-α biologics in treatment of rheumatoid arthritis: 5 years follow-up.
    Dewedar AM; Shalaby MA; Al-Homaid S; Mahfouz AM; Shams OA; Fathy A
    Int J Rheum Dis; 2012 Jun; 15(3):330-5. PubMed ID: 22709496
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Response to anti-tumour necrosis factor alpha blockade is associated with reduction of carotid intima-media thickness in patients with active rheumatoid arthritis.
    Del Porto F; Laganà B; Lai S; Nofroni I; Tinti F; Vitale M; Podestà E; Mitterhofer AP; D'Amelio R
    Rheumatology (Oxford); 2007 Jul; 46(7):1111-5. PubMed ID: 17449484
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.